RNS Number : 6718F MaxCyte, Inc. 23 March 2022 MaxCyte Reports Fourth Quarter and Full Year Financial Results MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, MD , March 23, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused
MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
RNS Number : 2726E MaxCyte, Inc. 10 March 2022 MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer Dr . Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. GAITHERSBURG, Md. Mar. 10, 2022 - MaxCyte, Inc.
Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
RNS Number : 0701E MaxCyte, Inc. 08 March 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 5270D MaxCyte, Inc. 03 March 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 1158D MaxCyte, Inc. 01 March 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Block Listing Return Gaithersburg, Maryland - 1 March 2022: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling platform technologies for ex-vivo cell engineering, makes
GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 7185C MaxCyte, Inc. 24 February 2022 MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022 GAITHERSBURG, MD , February 24, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing
RNS Number : 4691C MaxCyte, Inc. 22 February 2022 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name MAXCYTE, INC. UK or Non- UK Issuer Non- UK 2. Reason for Notification An acquisition or disposal of voting rights 3.
